Sempra (SRE) concluded trading on Wednesday at a closing price of $70.77, with 5.3 million shares of worth about $375.4 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -15.79% during that period and on March 26, 2025 the price saw a gain of about 2.40%. Currently the company’s common shares owned by public are about 651.46M shares, out of which, 651.00M shares are available for trading.
Stock saw a price change of -0.45% in past 5 days and over the past one month there was a price change of 0.18%. Year-to-date (YTD), SRE shares are showing a performance of -19.32% which increased to 1.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $64.89 but also hit the highest price of $95.77 during that period. The average intraday trading volume for Sempra shares is 5.46 million. The stock is currently trading 0.80% above its 20-day simple moving average (SMA20), while that difference is down -8.84% for SMA50 and it goes to -13.26% lower than SMA200.
Sempra (NYSE: SRE) currently have 651.46M outstanding shares and institutions hold larger chunk of about 91.30% of that.
The stock has a current market capitalization of $46.10B and its 3Y-monthly beta is at 0.69. PE ratio of stock for trailing 12 months is 16.02, while it has posted earnings per share of $4.42 in the same period. Its PEG reads 3.11 and has Quick Ratio of 0.49 while making debt-to-equity ratio of 1.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SRE, volatility over the week remained 1.87% while standing at 2.85% over the month.
Stock’s fiscal year EPS is expected to drop by -2.26% while it is estimated to increase by 10.49% in next year. EPS is likely to grow at an annualized rate of 5.15% for next 5-years, compared to annual growth of 3.92% made by the stock over the past 5-years.
Coverage by Jefferies stated Sempra (SRE) stock as a Hold in their note to investors on March 03, 2025, suggesting a price target of $77 for the stock. On February 27, 2025, Barclays Downgrade their recommendations, while on February 26, 2025, UBS Downgrade their ratings for the stock with a price target of $78. Stock get a Neutral rating from Goldman on February 26, 2025.
